Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
Amneal Pharmaceuticals (Nasdaq: AMRX) has announced a significant $1.5 million donation to multiple patient assistance foundations supporting individuals with Parkinson's disease during Parkinson's Awareness Month.
The donation aims to help offset out-of-pocket costs, including copayments, coinsurance, and deductibles for FDA-approved Parkinson's medications. This initiative addresses the financial challenges faced by over 10 million people worldwide affected by this progressive disease.
Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty at Amneal, emphasized that access to medication shouldn't be a barrier for Parkinson's patients. The company's contribution focuses on breaking down financial obstacles and improving treatment accessibility to help patients live fuller, more empowered lives.
Amneal Pharmaceuticals (Nasdaq: AMRX) ha annunciato una significativa a diverse fondazioni di assistenza ai pazienti che supportano le persone affette da malattia di Parkinson durante il Mese della Consapevolezza sul Parkinson.
La donazione mira ad aiutare a coprire i costi di tasca, inclusi i co-pagamenti, la coinsurance e le franchigie per i farmaci approvati dalla FDA per il Parkinson. Questa iniziativa affronta le sfide finanziarie affrontate da oltre 10 milioni di persone nel mondo colpite da questa malattia progressiva.
Joe Renda, Vice Presidente Senior e Chief Commercial Officer – Specialty di Amneal, ha sottolineato che l'accesso ai farmaci non dovrebbe essere un ostacolo per i pazienti affetti da Parkinson. Il contributo dell'azienda si concentra sulla rimozione degli ostacoli finanziari e sul miglioramento dell'accessibilità ai trattamenti per aiutare i pazienti a vivere vite più piene e empowerate.
Amneal Pharmaceuticals (Nasdaq: AMRX) ha anunciado una a múltiples fundaciones de asistencia para pacientes que apoyan a individuos con enfermedad de Parkinson durante el Mes de Concienciación sobre el Parkinson.
La donación tiene como objetivo ayudar a cubrir los costos de bolsillo, incluidos copagos, coinsurance y deducibles para medicamentos aprobados por la FDA para el Parkinson. Esta iniciativa aborda los desafíos financieros que enfrentan más de 10 millones de personas en todo el mundo afectadas por esta enfermedad progresiva.
Joe Renda, Vicepresidente Senior y Director Comercial – Specialty de Amneal, enfatizó que el acceso a la medicación no debería ser una barrera para los pacientes con Parkinson. La contribución de la empresa se centra en eliminar obstáculos financieros y mejorar la accesibilidad al tratamiento para ayudar a los pacientes a vivir vidas más plenas y empoderadas.
Amneal Pharmaceuticals (Nasdaq: AMRX)는 파킨슨병 인식의 달 동안 파킨슨병 환자를 지원하는 여러 환자 지원 재단에 150만 달러의 기부를 발표했습니다.
이 기부는 FDA 승인 파킨슨병 약물에 대한 본인 부담 비용, 즉 공동 지불금, 코보험 및 공제액을 상쇄하는 데 도움을 주기 위한 것입니다. 이 이니셔티브는 이 진행성 질환에 영향을 받는 전 세계 1천만 명 이상의 사람들이 직면한 재정적 문제를 해결하고자 합니다.
Amneal의 수석 부사장 겸 상업 책임자 – Specialty인 Joe Renda는 약물 접근이 파킨슨병 환자에게 장벽이 되어서는 안 된다고 강조했습니다. 회사의 기여는 재정적 장벽을 허물고 치료 접근성을 향상시켜 환자들이 더 충만하고 힘 있는 삶을 살도록 돕는 데 초점을 맞추고 있습니다.
Amneal Pharmaceuticals (Nasdaq: AMRX) a annoncé une dons significatif de 1,5 million de dollars à plusieurs fondations d'assistance aux patients soutenant les personnes atteintes de la maladie de Parkinson durant le Mois de la Sensibilisation à la Maladie de Parkinson.
Le don vise à aider à compenser les coûts à la charge des patients, y compris les co-paiements, les coassurances et les franchises pour les médicaments contre le Parkinson approuvés par la FDA. Cette initiative répond aux défis financiers auxquels sont confrontées plus de 10 millions de personnes dans le monde touchées par cette maladie progressive.
Joe Renda, Vice-Président Senior et Directeur Commercial – Specialty chez Amneal, a souligné que l'accès aux médicaments ne devrait pas être un obstacle pour les patients atteints de Parkinson. La contribution de l'entreprise se concentre sur la suppression des obstacles financiers et l'amélioration de l'accessibilité aux traitements pour aider les patients à vivre des vies plus pleines et plus autonomes.
Amneal Pharmaceuticals (Nasdaq: AMRX) hat eine bedeutende Spende von 1,5 Millionen Dollar an mehrere Patientenhilfsstiftungen angekündigt, die Personen mit Parkinson während des Parkinson-Bewusstseinsmonats unterstützen.
Die Spende zielt darauf ab, die Eigenkosten, einschließlich Zuzahlungen, Selbstbehalte und Franchisegebühren für von der FDA zugelassene Parkinson-Medikamente, auszugleichen. Diese Initiative geht auf die finanziellen Herausforderungen ein, mit denen über 10 Millionen Menschen weltweit konfrontiert sind, die von dieser fortschreitenden Krankheit betroffen sind.
Joe Renda, Senior Vice President und Chief Commercial Officer – Specialty bei Amneal, betonte, dass der Zugang zu Medikamenten kein Hindernis für Parkinson-Patienten sein sollte. Der Beitrag des Unternehmens konzentriert sich darauf, finanzielle Barrieren abzubauen und die Zugänglichkeit der Behandlung zu verbessern, um den Patienten zu helfen, ein erfüllteres und selbstbewussteres Leben zu führen.
- None.
- None.
Parkinson’s disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places significant financial strain on patients and their families. Amneal’s donations will be directed toward programs that offer funding support for out-of-pocket costs—including copayments, coinsurance, and deductibles—for FDA-approved Parkinson’s medications.
“Parkinson’s patients face numerous daily challenges, and access to medication should not be one of them,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty at Amneal Pharmaceuticals. “During Parkinson’s Awareness Month, we honor those living with this disease by taking action. We are proud to support organizations that are breaking down financial barriers and helping individuals receive the treatment they need to live fuller, more empowered lives. Together with our partners, we aim to foster hope, raise awareness, and improve outcomes for patients and their families.”
Patient assistance foundations have a long-standing impact in alleviating the financial burden of chronic disease. Through this initiative, Amneal is reinforcing its commitment to partnering with the Parkinson’s community and supporting programs that make a direct, positive impact on patient care.
Amneal encourages everyone to join in recognizing Parkinson’s Awareness Month and to support ongoing efforts to advance care, raise awareness, and accelerate progress toward a cure.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250411746912/en/
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
Media Contact
Randi Kahn
SVP, Corporate Affairs, Syneos Health
randi.kahn@syneoshealth.com
Source: Amneal Pharmaceuticals, Inc.
FAQ
How much did Amneal Pharmaceuticals (AMRX) donate for Parkinson's support in 2024?
What will Amneal's $1.5M donation be used for in Parkinson's patient care?
How many people worldwide are affected by Parkinson's disease according to AMRX?
What specific financial barriers does Amneal's donation address for Parkinson's patients?
How is AMRX supporting Parkinson's Awareness Month initiatives?
